Fig. 6 | Signal Transduction and Targeted Therapy

Fig. 6

From: Colony-stimulating factor 3 as a key mediator in the progression of idiopathic pulmonary fibrosis: a novel therapeutic target

Fig. 6

CSF3 neutralization restores alveolar type 2 cells and modulates immune cell recruitment in pulmonary fibrosis. a H&E, Masson’s trichrome staining, and immunostaining (pro-SP-C (pro-Surfactant protein C), and SP-A (Surfactant protein A), alveolar type 2 cell marker) of lung tissue from IT therapeutic and inhibition BLM model. The mouse CSF3 neutralizing antibody (FB-101m) was administered IP ×100; Scale bar 100 μm. ×400; Scale bar: 25 μm. b Masson’s trichrome staining and immunostaining (CD31; endothelial, MPO; neutrophil, CD86; macrophage, and CD45; pan-leukocyte) of lung tissue from C57BL/6 N mice intubated with BLM or PBS. The mouse CSF3 neutralizing antibody (FB-101m) was administered intraperitoneally. Masson’s trichrome Scale bar: 250 μm. Immunostaining Scale bar: 50 μm. c Masson’s trichrome staining and immunostaining (MPO; neutrophile) of lung tissue from CSF3+/+ and CSF3−/− mice intubated with BLM or PBS. Sacrifice was performed on each date, 7 days and 14 days after BLM treatment. (CTR n = 3; BLM 7, 14 days n = 5). Scale bar: 250 μm. d GSEA FDR values for features related to the recruitment of neutrophils, macrophages, lymphocytes, and leukocytes by high/low CSF3 expression. e Schematic summary of the mechanism of CSF3-induced fibrosis and proposed therapeutic strategy

Back to article page